Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Ireland / NCT07310914
Starting soon Phase 2

Implementation of an Advanced Telerehabilitation Solution for People With Multiple Sclerosis

NCT07310914 · tracked via the Priya Life Science Ireland tracker
Sponsor
Danish Multiple Sclerosis Hospitals
Phase
Phase 2
Started
2026-02-01
Last updated
2025-12-30

Condition(s) studied

Multiple Sclerosis

Investigational drug(s) / intervention(s)

TelerehabilitationPaper-based exercise

Telerehabilitation: Advanced telerehabilitation with a program made by specialized physiotherapists and delivered through the WizeCare system.

Paper-based exercise: Paper-based exercise instructions made by specialized physiotherapists.

Study summary

The overall purpose of the present study is to investigate the effect of an advanced telerehablitation system (TRS) in persons with multiple sclerosis on mobility. The advanced telerhabilitation system is based on AI components, and delivers instant feedback to the partcipants. If the project is successful, it can help optimize exercise for those persons with multiple sclerosis who are either not able or willing to travel to a clinical setting for exericse.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Definite diagnosis of MS according to the McDonald criteria (both relapse-remitting and progressive) * Expanded Disability Status Scale (EDSS) score of 2.5 to 6.5 or Patient Determined Disability Score (PDDS) of 2 to 6, indicating preservation of at least some ambulatory function, that is, the ability to walk 20 meters or more, independently, with or without the use of an assistive device * Willingness to travel to the local study site for the evaluation sessions, * Internet platform availability Exclusion Criteria: * comorbidities hindering participation in the study. * Individuals who have had a documented relapse and/or corticoid treatment during the past three months will be excluded, * Individuals with severe cognitive deficits who cannot follow simple instructions and/or consent.

Primary outcome measure(s)

  • 30 second sit to stand test — Baseline to 10 weeks
    Measure of lower extremity muscle power and a proxy measure of mobility

Trial sites (5)

FacilityCityRegionStatus
The Danish MS Hospitals, Haslev Haslev Denmark
The Danish MS Hospitals, Ry Ry Denmark
MS Ireland Dublin Ireland
Tel Aviv University Tel Aviv Israel
University of Cagliari Cagliari Italy

Other trials for the same condition

Pregnancy Exposure Registry for Vumerity (Diroximel Fumarate) Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07310914 on ClinicalTrials.gov ↗ ← All trials in Ireland